Company news
Bicara Therapeutics Inc. (NASDAQ:BCAX) news
Every Bicara Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
August 4, 2026
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 4, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 4, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ...
February 26, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Do...
February 19, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 5, 2026
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 12, 2026
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
December 15, 2025
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pi...
December 6, 2025
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp A...
December 1, 2025
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
October 13, 2025
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
October 13, 2025
Bicara Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
June 11, 2025
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO ...
June 1, 2025
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNS...
May 22, 2025
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
April 28, 2025
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society...
April 23, 2025
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 27, 2025
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
March 25, 2025
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025